Prostate Specific Antigen News and Research

RSS

Counting tumor cells in blood predicts treatment benefit in prostate cancer

Counting the number of tumor cells circulating in the bloodstream of patients with castration-resistant prostate cancer can accurately predict how well they are responding to treatment, new results show.

6 Jul 2008

Cancer cases up but survival more than doubles in breast and bowel cancer

The number of people surviving some of the most common types of cancer for at least five years has doubled since the National Health Service was founded 60 years ago.

3 Jul 2008

Seven elevated biomarkers predict prostate cancer risk with 86.6 percent reliability

A simple blood test screening for a panel of biomarkers can accurately predict whether a patient who has had prostate cancer surgery will have a recurrence or spread of the disease.

26 Jun 2008

Seven biomarkers that may help pinpoint prostate cancer recurrence found

A simple blood test may help doctors better predict whether prostate cancer will recur or spread in patients who have undergone surgery for the disease, UT Southwestern Medical Center researchers have found.

24 Jun 2008

Seven biomarkers found that predict with 86 percent accuracy prostate cancer recurrence

A simple blood test may help doctors better predict whether prostate cancer will recur or spread in patients who have undergone surgery for the disease, researchers at UT Southwestern Medical Center have found.

17 Jun 2008

Radiation therapy prolongs life in men with recurrent prostate cancer

Men whose tumors recur after prostate cancer surgery are three times more likely to survive their disease long term if they undergo radiotherapy within two years of the recurrence. Surprisingly, survival benefits were best in men whose new tumors were growing fastest, according to results of a 'look-back' study of 635 men by Johns Hopkins Medical Institutions researchers reported June 18 in the Journal of the American Medical Association.

17 Jun 2008

BN ImmunoTherapeutics starts clinical trials with prostate cancer vaccine

BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.

4 Jun 2008

Bavarian Nordic enters trials with prostate cancer vaccine

Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.

3 Jun 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone - the hormone that fuels prostate-cancer growth - via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.

2 Jun 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

1 Jun 2008

Finasteride for prostate cancer

A comprehensive re-evaluation of the largest prostate cancer prevention study ever completed produced new findings suggesting that men and their doctors should consider a more aggressive approach that includes finasteride to prevent the development of prostate cancer.

19 May 2008

Study shows prostate cancer gene 3 (PCA3) correlates with severity of prostate cancer

A study published in the May 2008 issue of the peer-reviewed Journal of Urology demonstrates that the prostate cancer gene 3 (PCA3) can be used to detect and stratify stage and grade of prostate cancer.

8 May 2008

Prostate cancer screening programme leads to bigger fall in death rates than surrounding areas

The expected number of deaths from prostate cancer more than halved in the Tyrol after a programme was introduced to improve early detection and treatment of the disease, according to research published in April issue of the urology journal BJU International.

22 Apr 2008

Screening or treatment for prostate cancer?

Is screening or treatment for prostate cancer the reason for decreased mortality in the USA, compared to the UK?

18 Apr 2008

Scientists cast doubt on value of screening for prostate cancer

Even though deaths from prostate cancer death have fallen in the U.S. since screening became more common, new research is suggesting that this does not justify the need for such tests.

17 Apr 2008

New study confirms that PROGENSA PCA3 can improve accuracy of prostate cancer diagnosis

New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.

20 Mar 2008

Biopsy techniques have made PSA test less predictive

Prostate specific antigen (PSA) levels typically have correlated with prostate biopsy results in the detection of prostate cancer, but that correlation no longer exists for men with a normal prostate exam, according to a new study published in the April 15, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society.

11 Mar 2008